Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Return on Capital Employed for 6 consecutive years, with 0.44% as the latest value for Q2 2025.

  • On a quarterly basis, Return on Capital Employed changed N/A to 0.44% in Q2 2025 year-over-year; TTM through May 2025 was 0.44%, a N/A change, with the full-year FY2024 number at 0.51%, up 1.0% from a year prior.
  • Return on Capital Employed was 0.44% for Q2 2025 at Nurix Therapeutics, down from 0.43% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.22% in Q2 2021 to a low of 0.63% in Q4 2023.
  • A 5-year average of 0.41% and a median of 0.44% in 2025 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: fell -26bps in 2022, then increased 20bps in 2024.
  • Nurix Therapeutics' Return on Capital Employed stood at 0.28% in 2021, then tumbled by -78bps to 0.5% in 2022, then dropped by -26bps to 0.63% in 2023, then skyrocketed by 32bps to 0.43% in 2024, then dropped by -2bps to 0.44% in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Return on Capital Employed are 0.44% (Q2 2025), 0.43% (Q4 2024), and 0.45% (Q3 2024).